Takeda Pharmaceutical (TAK) Fundamentals 2026 — P/E 45.5x, Revenue Analysis | SniperIQ

6.95 on the NYSE. This SniperIQ fundamentals page covers Takeda Pharmaceutical's valuation (P/E 45.5x, P/B 1.1x), profitability (net margin 4.3%), revenue (¥4.78T in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Full research coverage

• 8-Quarter Revenue & Margin Trend
• Debt Maturity & Coverage
• Peer Valuation Comparison
• Free Cash Flow & Owner Earnings
• AI Signal + Institutional Flow
• DCF Valuation Model

Frequently Asked Questions

What is Takeda Pharmaceutical's market cap?

Takeda Pharmaceutical (TAK) has a market capitalization of approximately $53.9B, trading at

6.95 on the NYSE. Market cap moves with the live share price.

What is Takeda Pharmaceutical's P/E ratio?

Takeda Pharmaceutical's trailing twelve-month P/E ratio is 45.5x, with a price-to-book (P/B) of 1.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Takeda Pharmaceutical?

Takeda Pharmaceutical runs a net profit margin of 4.3%, a gross margin of 58.8%, and an operating margin of 10.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Takeda Pharmaceutical generate?

Takeda Pharmaceutical reported revenue of ¥4.78T for fiscal year 2025, with net income of ¥203.3B and earnings per share (EPS) of 63.91. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Takeda Pharmaceutical pay a dividend?

Takeda Pharmaceutical offers a trailing dividend yield of about 3.6%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is Takeda Pharmaceutical financially healthy?

Takeda Pharmaceutical carries a debt-to-equity ratio of 0.63x and a current ratio of 1.27x, with a market beta of 0.09. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Takeda Pharmaceutical a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Takeda Pharmaceutical (TAK) the key facts are: market cap $53.9B, P/E 45.5x, revenue ¥4.78T, 52-week range 12.99-18.9. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.